Valeo Pharma (TSE:VPH) has released an update.
Valeo Pharma Inc. reported a decrease in third quarter revenues by 11% compared to the previous year, down to $12.6 million, largely due to the termination of XIIDRA commercialization. Despite this, the company saw a healthy growth trend in its continuing business with a 9% increase and a 40% reduction in adjusted EBITDA loss, signaling a possible turnaround and growth in their core brands.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.
